Page last updated: 2024-10-16

adenine and Liver Cirrhosis

adenine has been researched along with Liver Cirrhosis in 136 studies

Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.

Research Excerpts

ExcerptRelevanceReference
"To explore clinical efficacy of Yiguanjian Decoction (YD) combined Adefovir Dipivoxil Tablet (ADT) in treating HBeAg negative chronic viral hepatitis B (CVHB) active compensated liver cirrhosis (LC) patients."9.22[Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients]. ( Bao, ZY; Duan, SH; Liu, MS; Wang, L; Yuan, XD, 2016)
"To compare the efficacies ofentecavir and adefovir in patients with chronic hepatitis B (CHB) and cirrhosis when administered as monotherapies using a 240-week course."9.20[A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis]. ( Gao, Y; Han, T; Lian, J; Liu, F; Lyu, H; Wang, F; Xiang, H, 2015)
"To compare efficacy of combined lamivudine (LAM) and adefovir dipivoxil (ADV) therapy with that of entecavir (ETV) monotherapy for hepatitis B virus (HBV)-related decompensated liver cirrhosis."9.17De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. ( Chen, JY; Hu, JH; Jia, HY; Li, LJ; Lian, JS; Lu, YF; Xiang, DR; Yang, YD; Yu, L; Zeng, LY; Zhang, YM; Zheng, L, 2013)
"To study the changes of experimental markers of hepatic fibrosis in patients with chronic hepatitis B treated by Dahuang Zhechong Wan combined with adefovir dipivoxil."9.16[Experimental study on effect of dahuang zhechong wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B]. ( Chang, Y; Zhang, L, 2012)
"A large clinic cohort of chronic hepatitis B cirrhotic patients were enrolled in a treatment program of lamivudine ± adefovir therapy."9.15Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis. ( Aung, MO; Dan, YY; Fernandes, M; Lai, V; Lee, GH; Lee, YM; Lim, SG; Low, HC; Mak, B; Sutedja, D, 2011)
"This prospective randomized pilot study was conducted in Lok Nayak Hospital, New Delhi, involving 30 patients of chronic hepatitis B (both e antigen positive and negative); 15 were randomly selected to receive either adefovir or lamivudine for a period of 6 months."9.15Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis. ( Asim, M; Das, BC; Gondal, R; Kar, P; Medhi, S; Pradeep Kumar, S, 2011)
"To investigate the efficacy and safety of adefovir dipivoxil (ADV) in treating hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis."9.13[Adefovir dipivoxil treatment of hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis]. ( Chen, YS; Jin, ZJ; Li, DF; Qiao, LM; Zhou, J, 2008)
"To evaluate the efficacy and safety of 48 weeks adefovir dipivoxil (ADV) treatment for chronic hepatitis patients with cirrhosis in their decompensation period."9.12[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period]. ( Gong, ZJ; Hu, DF; Yang, Q, 2007)
"Treatment with adefovir dipivoxil for 48 weeks resulted in clinical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B that was lost when treatment was discontinued."9.12Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. ( Arterburn, S; Borroto-Esoda, K; Brosgart, CL; Chang, TT; Chuck, SL; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC, 2006)
"The purpose of this prospective study was to evaluate the efficacy and safety of adefovir dipivoxil with or without ongoing lamivudine in decompensated lamivudine-resistant chronic hepatitis B patients."9.11Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. ( Choi, WB; Chung, YH; Kim, KM; Lee, HC; Lee, YS; Lim, YS; Suh, DJ, 2005)
"Treatment with adefovir dipivoxil for 48 weeks resulted in histologic, virologic, and biochemical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B."9.11Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. ( Arterburn, S; Brosgart, CL; Chang, TT; Currie, G; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC; Xiong, S, 2005)
" Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance."9.10Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. ( Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P, 2002)
"To compare the reduction of hepatocellular carcinoma (HCC) risk between long-term treatment of entecavir and low genetic barrier antiviral agents in hepatitis B virus (HBV)-related cirrhotic patients."7.91Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching. ( Li, T; Lin, C; Qu, Y; Wang, L; Wang, Y; Yang, B, 2019)
"This study assessed the antiviral efficacy and safety of tenofovir disoproxil fumarate (TDF) for up to 12 months in Korean treatment-naïve chronic hepatitis B (CHB) patients."7.80Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. ( Ahn, SH; Ahn, SS; Chon, YE; Han, KH; Kim, BK; Kim, DY; Kim, SU; Park, JY, 2014)
"Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV)."7.80Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. ( Cho, M; Choi, JY; Han, KH; Hwang, JS; Kim, BI; Kim, DJ; Lee, CK; Lee, HJ; Paik, SW; Suh, DJ; Um, SH; Woo, HY; Yoon, SK, 2014)
"One advanced schistosomiasis patient with hepatitis B cirrhosis was treated with lamivudine and adefovir dipivoxil and the curative effect was satisfied."7.79[Treatment of one advanced schistosomiasis patient with hepatitis B cirrhosis by lamivudine and adefovir dipivoxil]. ( Li, YC, 2013)
"Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB)."7.79Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients. ( Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Lee, CH, 2013)
"Data concerning the outcome of lamivudine-resistant (LAM-R) chronic hepatitis B (CHB) patients with compensated cirrhosis under adefovir (ADV) treatment are limited."7.75Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. ( Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Vezali, E, 2009)
"To evaluate the efficacy and safety of adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD motif mutation during lamivudine therapy."7.73[Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation]. ( Su, GG; Ying, MF; Zhao, NF; Zhou, Y, 2005)
"Adefovir dipivoxil is effective in patients with lamivudine-resistant hepatitis B virus (HBV)."7.73[Efficacy and safety of adefovir dipivoxil in patients with decompensated liver cirrhosis with Lamivudine resistance compared to patients with compensated liver disease]. ( Choi, MS; Koh, KC; Lee, JH; Moon, W; Moon, YM; Paik, SW; Rhee, JC; Shim, SG; Yoo, BC, 2005)
"Antiviral treatment can be complex in decompensated hepatitis B virus (HBV) cirrhosis because of potential emergence of lamivudine-resistant mutants and worsening liver function, and to multifactorial nephrotoxicity."7.73Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results. ( Cañas, C; Casais, LA; Casanova, A; Chahri, N; Figueras, J; Gornals, J; Lopez, C; Taltavull, TC; Verdura, B, 2005)
"Lamivudine is a treatment option for the therapy of chronic hepatitis B with an excellent safety profile."7.72Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. ( Flemming, P; Klempnauer, J; Manns, MP; Nashan, B; Niemann, P; Rohde, P; Tillmann, HL; Tischendorf, JJ; Trautwein, C; Wiegand, J, 2004)
" A 40-year-old liver transplant recipient with hepatitis B virus reinfection, resistance to lamivudine, and fibrosing cholestatic hepatitis complicated by terminal renal impairment and spontaneous bacterial peritonitis was treated with adefovir dipivoxil 10 mg after every dialysis."7.72Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. ( Barg-Hock, H; Becker, T; Bleck, JS; Bock, CT; Böker, KH; Flemming, P; Klempnauer, J; Manns, MP; Rosenau, J; Tillmann, HL; Trautwein, C, 2003)
"In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores."5.24Effects of the combined administration of entecavir and adefovir dipivoxil to improve hepatic fibrosis in hepatitis B patients with interferon resistance. ( Chang, S; Chen, B; Qiu, L; Shen, F; Sun, Y; Wu, K; Yu, L, 2017)
"To explore clinical efficacy of Yiguanjian Decoction (YD) combined Adefovir Dipivoxil Tablet (ADT) in treating HBeAg negative chronic viral hepatitis B (CVHB) active compensated liver cirrhosis (LC) patients."5.22[Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients]. ( Bao, ZY; Duan, SH; Liu, MS; Wang, L; Yuan, XD, 2016)
"To compare the efficacies ofentecavir and adefovir in patients with chronic hepatitis B (CHB) and cirrhosis when administered as monotherapies using a 240-week course."5.20[A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis]. ( Gao, Y; Han, T; Lian, J; Liu, F; Lyu, H; Wang, F; Xiang, H, 2015)
"We examined the durability of the virological response after discontinuing lamivudine (LVD) in chronic hepatitis B (CHB) patients with LVD-resistant hepatitis B virus (HBV), who responded to LVD plus adefovir (ADV) combination therapy, and the outcome of switching to ADV monotherapy compared to maintaining combination therapy."5.19Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Kim, HS; Kim, MN; Kim, SU; Lee, CK; Lee, S; Park, JY, 2014)
"This study assessed the clinical efficacy of lamivudine and adefovir dipivoxil combined with autologous bone marrow stem cell transplantation as treatment for patients with hepatitis B and decompensated liver cirrhosis."5.19Curative effect of combined lamivudine, adefovir dipivoxil, and stem cell transplantation on decompensated hepatitis B cirrhosis. ( He, CP; Huang, LW; Ling, K; Liu, L; Wang, XM; Wen, QM; Yan, Y; Zhou, HC; Zhou, J, 2014)
"To investigate the efficacy and safety of combined de novo lamivudine (LAM) and adefovir dipivoxil (ADV) therapy in hepatitis B virus (HBV)-related decompensated liver cirrhosis patients."5.17Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. ( Chen, Y; Li, LJ; Lv, GC; Sheng, JF; Yang, YD; Yao, JM; Zheng, L, 2013)
"To compare efficacy of combined lamivudine (LAM) and adefovir dipivoxil (ADV) therapy with that of entecavir (ETV) monotherapy for hepatitis B virus (HBV)-related decompensated liver cirrhosis."5.17De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. ( Chen, JY; Hu, JH; Jia, HY; Li, LJ; Lian, JS; Lu, YF; Xiang, DR; Yang, YD; Yu, L; Zeng, LY; Zhang, YM; Zheng, L, 2013)
"To study the changes of experimental markers of hepatic fibrosis in patients with chronic hepatitis B treated by Dahuang Zhechong Wan combined with adefovir dipivoxil."5.16[Experimental study on effect of dahuang zhechong wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B]. ( Chang, Y; Zhang, L, 2012)
"A large clinic cohort of chronic hepatitis B cirrhotic patients were enrolled in a treatment program of lamivudine ± adefovir therapy."5.15Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis. ( Aung, MO; Dan, YY; Fernandes, M; Lai, V; Lee, GH; Lee, YM; Lim, SG; Low, HC; Mak, B; Sutedja, D, 2011)
"This prospective randomized pilot study was conducted in Lok Nayak Hospital, New Delhi, involving 30 patients of chronic hepatitis B (both e antigen positive and negative); 15 were randomly selected to receive either adefovir or lamivudine for a period of 6 months."5.15Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis. ( Asim, M; Das, BC; Gondal, R; Kar, P; Medhi, S; Pradeep Kumar, S, 2011)
"To investigate the efficacy and safety of adefovir dipivoxil (ADV) in treating hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis."5.13[Adefovir dipivoxil treatment of hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis]. ( Chen, YS; Jin, ZJ; Li, DF; Qiao, LM; Zhou, J, 2008)
"To evaluate the efficacy and safety of 48 weeks adefovir dipivoxil (ADV) treatment for chronic hepatitis patients with cirrhosis in their decompensation period."5.12[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period]. ( Gong, ZJ; Hu, DF; Yang, Q, 2007)
"Treatment with adefovir dipivoxil for 48 weeks resulted in clinical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B that was lost when treatment was discontinued."5.12Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. ( Arterburn, S; Borroto-Esoda, K; Brosgart, CL; Chang, TT; Chuck, SL; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC, 2006)
"Treatment with adefovir dipivoxil for 48 weeks resulted in histologic, virologic, and biochemical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B."5.11Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. ( Arterburn, S; Brosgart, CL; Chang, TT; Currie, G; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC; Xiong, S, 2005)
"The purpose of this prospective study was to evaluate the efficacy and safety of adefovir dipivoxil with or without ongoing lamivudine in decompensated lamivudine-resistant chronic hepatitis B patients."5.11Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. ( Choi, WB; Chung, YH; Kim, KM; Lee, HC; Lee, YS; Lim, YS; Suh, DJ, 2005)
" Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance."5.10Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. ( Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P, 2002)
"Antiviral therapy using newer nucleos(t)ide analogues with lower resistance rates such as entecavir or tenofovir could suppress hepatitis B virus (HBV) replication, improve liver function, delay or obviate the need for liver transplantation in some patients, and reduce the risk of HBV recurrence."4.90Prevention of hepatitis B virus reinfection in liver transplant recipients. ( Roche, B; Samuel, D, 2014)
"Among the six drugs licensed for the treatment of chronic hepatitis B in the US, the preferred agents in 2008 will include entecavir, peginterferon alfa-2a, possibly telbivudine, and tenofovir following licensure."4.84Review article: current antiviral therapy of chronic hepatitis B. ( Ayoub, WS; Keeffe, EB, 2008)
" Chronic hepatitis C can be treated preferably with a combination therapy (pegylated interferons + Ribavirin)."4.82[Hepatitis: associated diseases. Risk groups -- prevention -- treatment]. ( Maier, KP, 2003)
"To compare the reduction of hepatocellular carcinoma (HCC) risk between long-term treatment of entecavir and low genetic barrier antiviral agents in hepatitis B virus (HBV)-related cirrhotic patients."3.91Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching. ( Li, T; Lin, C; Qu, Y; Wang, L; Wang, Y; Yang, B, 2019)
" Drugs currently used against HBV include IFN-α that decreases viremia, inflammation and the growth of liver fibrosis, and adefovir that decreases the viral load."3.88Chronic hepatitis B virus and liver fibrosis: A mathematical model. ( Friedman, A; Siewe, N, 2018)
"None of the patients developed lactic acidosis during follow-up [median: 58 (6-155) months]."3.85Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis. ( Aggeletopoulou, I; Anastassiou, ED; Assimakopoulos, S; Gogos, C; Kalafateli, M; Labropoulou-Karatza, C; Mandellou, M; Taprantzi, D; Thomopoulos, K; Triantos, C; Tselekouni, P; Tsiaoussis, G; Vourli, G, 2017)
"This study assessed the antiviral efficacy and safety of tenofovir disoproxil fumarate (TDF) for up to 12 months in Korean treatment-naïve chronic hepatitis B (CHB) patients."3.80Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. ( Ahn, SH; Ahn, SS; Chon, YE; Han, KH; Kim, BK; Kim, DY; Kim, SU; Park, JY, 2014)
"Since the licensing of lamivudine in 1999, the treatment of chronic hepatitis B has been revolutionized by the introduction of oral nucleoside and nucleotide analogues (NAs), which act as inhibitors of the HBV polymerase."3.80Antiviral therapy of chronic hepatitis B. ( Berg, T; van Bömmel, F, 2014)
"Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV)."3.80Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. ( Cho, M; Choi, JY; Han, KH; Hwang, JS; Kim, BI; Kim, DJ; Lee, CK; Lee, HJ; Paik, SW; Suh, DJ; Um, SH; Woo, HY; Yoon, SK, 2014)
"Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB)."3.79Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients. ( Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Lee, CH, 2013)
" We investigated the long-term safety and efficacy of these antiviral drugs in patients with chronic hepatitis B virus (HBV) infection, with compensated or decompensated cirrhosis, and compared results with those from lamivudine."3.79Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. ( Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O, 2013)
"We studied the cost-effectiveness of tenofovir and entecavir in e antigen positive (CHBe+) and negative (CHBe-) chronic hepatitis B."3.79Should chronic hepatitis B be treated as early as possible? ( Colle, I; Gamil, M; Horsmans, Y; Hulstaert, F; Nevens, F; Schwierz, C; Thiry, N; Van de Sande, S, 2013)
"One advanced schistosomiasis patient with hepatitis B cirrhosis was treated with lamivudine and adefovir dipivoxil and the curative effect was satisfied."3.79[Treatment of one advanced schistosomiasis patient with hepatitis B cirrhosis by lamivudine and adefovir dipivoxil]. ( Li, YC, 2013)
"Before tenofovir approval for chronic hepatitis B therapy, the clinical management of patients with suboptimal response or virological breakthrough during combination treatment with lamivudine and adefovir dipivoxil was a difficult clinical challenge."3.78High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on. ( Aldini, R; Azzaroli, F; Buonfiglioli, F; Galli, S; Giandinoto, M; Lisotti, A; Mazzella, G; Montagnani, M; Turco, L, 2012)
"Adefovir dipivoxil, an acyclic nucleoside analogue, has been approved for the treatment of patients with chronic hepatitis B."3.76[A case of osteomalacia related to adefovir in a patient with chronic hepatitis B]. ( Ahn, SY; Choe, WH; Choi, YH; Jang, YM; Kim, BK; Ko, SY; Kwon, SY; Lee, CH, 2010)
"Data on the efficacy of adefovir dipivoxil (ADV) in elderly and cirrhotic patients with lamivudine-resistant (LAM-R) chronic hepatitis B are scarce."3.75Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. ( Bailly, F; Beaugrand, M; Benhamou, Y; Marcellin, P; Maynard, M; Monchecourt, F; Parvaz, P; Trepo, C; Trylesinski, A; Zarski, JP; Zoulim, F, 2009)
"Data concerning the outcome of lamivudine-resistant (LAM-R) chronic hepatitis B (CHB) patients with compensated cirrhosis under adefovir (ADV) treatment are limited."3.75Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. ( Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Vezali, E, 2009)
"Antiviral treatment can be complex in decompensated hepatitis B virus (HBV) cirrhosis because of potential emergence of lamivudine-resistant mutants and worsening liver function, and to multifactorial nephrotoxicity."3.73Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results. ( Cañas, C; Casais, LA; Casanova, A; Chahri, N; Figueras, J; Gornals, J; Lopez, C; Taltavull, TC; Verdura, B, 2005)
"To evaluate the efficacy and safety of adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD motif mutation during lamivudine therapy."3.73[Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation]. ( Su, GG; Ying, MF; Zhao, NF; Zhou, Y, 2005)
"Adefovir dipivoxil is effective in patients with lamivudine-resistant hepatitis B virus (HBV)."3.73[Efficacy and safety of adefovir dipivoxil in patients with decompensated liver cirrhosis with Lamivudine resistance compared to patients with compensated liver disease]. ( Choi, MS; Koh, KC; Lee, JH; Moon, W; Moon, YM; Paik, SW; Rhee, JC; Shim, SG; Yoo, BC, 2005)
"Lamivudine is a treatment option for the therapy of chronic hepatitis B with an excellent safety profile."3.72Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. ( Flemming, P; Klempnauer, J; Manns, MP; Nashan, B; Niemann, P; Rohde, P; Tillmann, HL; Tischendorf, JJ; Trautwein, C; Wiegand, J, 2004)
"Resistant hepatitis B virus (HBV) strains develop in 30% of liver transplant recipients treated with lamivudine within 2 years from the time of transplantation."3.72Tenofovir therapy for lamivudine resistance following liver transplantation. ( Duncan, R; Lau, DT; Madariaga, JR; Montalbano, M; Muslu, H; Neff, GW; Nery, C; Nery, J; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Shire, NJ; Tzakis, AG, 2004)
" A 40-year-old liver transplant recipient with hepatitis B virus reinfection, resistance to lamivudine, and fibrosing cholestatic hepatitis complicated by terminal renal impairment and spontaneous bacterial peritonitis was treated with adefovir dipivoxil 10 mg after every dialysis."3.72Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. ( Barg-Hock, H; Becker, T; Bleck, JS; Bock, CT; Böker, KH; Flemming, P; Klempnauer, J; Manns, MP; Rosenau, J; Tillmann, HL; Trautwein, C, 2003)
"Current treatments for chronic hepatitis B (CHB) include pegylated interferon alpha (PEG-IFN-α) which is an immune modulator, and nucleos(t)ide analogs (NAs) which directly inhibit HBV DNA polymerase."2.84Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial. ( Guo, H; Jiao, J; Liu, Z; Qi, W; Wang, J; Wang, X; Xu, Y; Yu, F; Zhao, P; Zhou, C, 2017)
"Interferon is the only effective treatment for chronic hepatitis D virus (HDV) infection."2.80Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. ( Bozkaya, H; Dalekos, GN; Deda, X; Gürel, S; Heidrich, B; Idilman, R; Keskin, O; Manns, M; Pehlivan, S; Tabak, F; Tüzün, A; Wedemeyer, H; Yalçın, K; Yurdaydin, C; Zachou, K; Zeuzem, S, 2015)
"Patients with chronic hepatitis B (HBeAg+ and HBeAg-) randomized in two trials of adefovir (ADV) vs placebo, with available paired liver biopsies and FT-AT at baseline and after 48 weeks of treatment were included."2.74Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. ( Benhamou, Y; Hadziyannis, S; Marcellin, P; Ngo, Y; Poynard, T; Ratziu, V, 2009)
"The role of hepatocellular carcinoma (HCC) in HBV recurrence remains unclear."2.73Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. ( Brechot, C; Castaing, D; Dussaix, E; Fallot, G; Faria, LC; Ferrari, TC; Gigou, M; Guettier, C; Roche, B; Roque-Afonso, AM; Samuel, D; Sebagh, M, 2008)
"For chronic HBV carrier liver cirrhosis patients, a successful vaccine response can only be achieved in selected patients, such as those treated with experimentally reduced immunosuppression protocols."2.52Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. ( Takaki, A; Yagi, T; Yasunaka, T, 2015)
"Although a rather benign course of chronic hepatitis B virus (HBV) infection during childhood has been described, 3-5% and 0."2.50Management of chronic hepatitis B in children: an unresolved issue. ( Cainelli, F; Comparcola, D; Della Corte, C; Nobili, V; Vento, S, 2014)
"Specialized treatment of CHB in pregnancy, coinfection, decompensated cirrhosis, and posttransplant is safe and effective."2.48New advances in chronic hepatitis B. ( Lee, WM; Tujios, SR, 2012)
"Those at risk for liver disease progression are usually treated with a combination of interferon (IFN) and ribavirin (RBV), which is not highly effective; it has low rates of sustained virologic response (SVR), especially for coinfected patients with HCV genotype 1 and those of African descent."2.48Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. ( Naggie, S; Sulkowski, MS, 2012)
"The main goal for treatment of chronic hepatitis B is to prevent complications such as liver cirrhosis or hepatocellular carcinoma."2.44Treatment of chronic hepatitis B infection: an update of Swedish recommendations. ( Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J, 2008)
"In patients with liver cirrhosis (Child B and C) only nucleos(t)ides should be used."2.43[Therapy of hepatitis B virus infection]. ( Trautwein, C, 2006)
"Regardless of prophylaxis, the risk of recurrence is associated with pre-graft viral load."2.43[Liver transplantation for complications of hepatitis B]. ( Roche, B; Samuel, D, 2006)
"Lamivudine appears to be a safe and effective antiviral agent, which may improve or stabilize liver disease in selected patients with advanced cirrhosis and active HBV replication."2.42Management of patients with decompensated HBV cirrhosis. ( Fontana, RJ, 2003)
"However, the role of β-arrestins in liver fibrosis remains unknown."1.51β-Arrestin1 enhances liver fibrosis through autophagy-mediated Snail signaling. ( Huang, X; Jiang, J; Liu, H; Lu, Y; Tan, S; Wu, B; Xu, M, 2019)
"Mortality and complications including hepatocellular carcinoma are associated primarily with cirrhosis and age, but not with HBeAg status or viral load probably because modern therapies considerably reduce viral replication in almost all patients."1.43Long-term follow-up of HBsAg-positive patients in Germany. ( Amani, A; Niederau, C; Thiel, A, 2016)
"Liver fibrosis was measured using elastometry."1.40Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. ( Barreiro, P; Fernández-Montero, JV; Labarga, P; Mendoza, Cd; Sierra-Enguita, R; Soriano, V; Vispo, E, 2014)
"Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) is the most frequent and difficult-to-treat viral hepatitis worldwide."1.39Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis. ( Bonino, F; Brunetto, MR; Caputo, A; Coco, B; Espinos, B; Iannazzo, S; Latour, A; Rossetti, F, 2013)
"Data on liver fibrosis evolution in HIV-HBV-coinfected patients treated with tenofovir disoproxil fumarate (TDF) are scarce."1.36Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. ( Bonnard, P; Boyd, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Lasnier, E; Meynard, JL; Miailhes, P; Molina, JM; Wendum, D, 2010)
" Mean HBIg half-life was 21."1.36Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. ( Andreone, P; Bacci, M; Burra, P; Canova, D; Cursaro, C; Fiorentino, B; Guazzini, S; Marengo, A; Marzano, A; Riili, A; Volpes, R, 2010)
"Chronic hepatitis B affects 5-10% of HIV patients in Western countries."1.35Hepatitis B in HIV patients: what is the current treatment and what are the challenges? ( Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E, 2009)
"A 36 year old man with chronic hepatitis B and cirrhosis was admitted in our Department for the onset of jaundice, ascites and ALT flare (x 35 u."1.35Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare. ( Brancaccio, G; Gaeta, GB; Nardiello, S; Precone, V; Sgrò, G; Stornaiuolo, G, 2009)

Research

Studies (136)

TimeframeStudies, this research(%)All Research%
pre-19906 (4.41)18.7374
1990's2 (1.47)18.2507
2000's54 (39.71)29.6817
2010's73 (53.68)24.3611
2020's1 (0.74)2.80

Authors

AuthorsStudies
Furukawa, S1
Yamaguchi, M1
Ooka, A1
Kikuchi, H1
Ishikawa, T1
Saito, SY1
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y3
Wang, J7
Huang, L2
Hu, K1
Liu, H5
Wang, H5
Guo, Z1
Song, Y1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S1
Cheng, T1
Zhou, X1
Wang, B4
Zhang, Q4
Wu, X3
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J4
Gai, QY3
Wang, W2
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X6
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J5
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J2
Jiang, H1
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X4
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y5
Liu, Z4
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Zhang, X6
Xu, N1
Wang, R1
Liu, S1
He, H1
Dong, X2
Yang, M3
Yang, Q3
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L2
Yang, X1
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH4
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C2
Gilson, E1
Ye, J1
Lu, Y2
Yan, R1
Zhang, Y6
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X2
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y10
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L4
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X3
Huang, X3
Xu, H2
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J3
Li, J8
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Liu, Y8
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS2
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H1
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J2
Chu, S1
Pan, Q1
Li, D2
Zheng, S2
Ma, L1
Wang, L5
Hu, T1
Wang, F2
Han, Z1
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y3
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y4
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z2
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J4
Guo, W1
Liu, M2
Liu, T2
Chen, D6
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W2
Zhang, S2
Feng, J2
Qi, N1
Shen, G1
Ren, H2
Shang, Q1
Zhao, W2
Yang, Z2
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J1
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C2
Liu, C2
Liu, W1
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y2
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q1
Yuan, X1
Nie, W1
Yang, J3
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H2
Cui, Y1
Zhang, L4
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Li, C2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X3
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J1
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH2
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q3
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z2
Liang, H1
Xu, X1
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J2
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y4
Xue, H1
Zhang, W2
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M2
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J1
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J2
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L1
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L3
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H2
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y2
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Hercun, J1
Koh, C1
Heller, T1
Triantos, C1
Kalafateli, M1
Aggeletopoulou, I1
Mandellou, M1
Assimakopoulos, S1
Tselekouni, P1
Taprantzi, D1
Tsiaoussis, G1
Vourli, G1
Anastassiou, ED1
Gogos, C1
Labropoulou-Karatza, C1
Thomopoulos, K1
Qi, W1
Yu, F1
Guo, H1
Zhao, P1
Wu, K1
Shen, F1
Qiu, L1
Chen, B1
Chang, S1
Oh, H1
Jun, DW1
Kong, Y1
Ma, H1
You, H1
Ou, X1
Jia, J1
Bai, F1
Huang, Q1
Nie, J1
Lu, S1
Lu, C1
Zhuo, L1
Lu, Z1
Lin, X1
Friedman, A1
Siewe, N1
Tan, S1
Xu, M1
Wu, B1
Yan, JY1
Li, ZQ1
Yu, ZJ1
Kan, QC1
Li, T1
Qu, Y1
Lin, C1
Yang, B1
Sutherland, N1
Li Wai Suen, CFD1
Mills, C1
Lokan, J1
Sinclair, M1
Tada, T1
Toyoda, H1
Yasuda, S1
Miyake, N1
Kumada, T1
Kurisu, A1
Ohisa, M1
Akita, T1
Tanaka, J1
Iannazzo, S1
Coco, B1
Brunetto, MR1
Rossetti, F1
Caputo, A1
Latour, A1
Espinos, B1
Bonino, F1
Li, YC1
Lv, GC1
Yao, JM1
Yang, YD2
Zheng, L2
Sheng, JF1
Chen, Y2
Li, LJ2
Srivastava, M1
Rungta, S1
Dixit, VK1
Shukla, SK1
Singh, TB1
Jain, AK1
Peng, H1
Tong, S1
Yin, W1
Hu, P1
Lian, JS1
Zeng, LY1
Chen, JY1
Jia, HY1
Zhang, YM1
Xiang, DR1
Hu, JH1
Lu, YF1
Kim, JH2
Ko, SY3
Choe, WH3
Kwon, SY3
Lee, CH3
Czech, B1
Dettmer, K1
Valletta, D1
Saugspier, M1
Koch, A1
Stevens, AP1
Thasler, WE1
Müller, M1
Oefner, PJ1
Bosserhoff, AK1
Hellerbrand, C1
Kim, MN1
Lee, CK2
Ahn, SH2
Lee, S1
Kim, SU2
Kim, DY2
Kim, HS1
Han, KH3
Chon, CY1
Park, JY2
Calvaruso, V1
Craxì, A2
Triolo, M1
Della Corte, C2
Colombo, M4
Price, J1
Liu, L1
Yan, Y1
Zhou, J2
Huang, LW1
He, CP1
Ling, K1
Zhou, HC1
Wen, QM1
Wang, XM1
Nobili, V1
Comparcola, D1
Cainelli, F1
Vento, S1
Cholongitas, E2
Goulis, I2
Antoniadis, N2
Fouzas, I2
Imvrios, G2
Papanikolaou, V2
Akriviadis, E2
Woo, HY1
Choi, JY1
Yoon, SK1
Suh, DJ2
Paik, SW2
Um, SH1
Kim, BI1
Lee, HJ2
Cho, M1
Kim, DJ1
Hwang, JS1
van Bömmel, F1
Berg, T1
Roche, B3
Samuel, D4
Soriano, V3
Vispo, E3
Sierra-Enguita, R1
Mendoza, Cd1
Fernández-Montero, JV1
Labarga, P2
Barreiro, P3
Tsai, NC1
Marcellin, P6
Buti, M2
Washington, MK1
Lee, SS2
Chan, S1
Trinh, H1
Flaherty, JF1
Kitrinos, KM1
Dinh, P1
Charuworn, P1
Subramanian, GM1
Gane, E1
Grizzi, F1
Desmet, VJ1
Coffin, CS1
Rezaeeaval, M1
Pang, JX1
Alcantara, L1
Klein, P1
Burak, KW1
Myers, RP1
Ahn, SS1
Chon, YE1
Kim, BK3
Gu, EL1
Yu, YQ1
Wang, JL1
Ji, YY1
Ma, XY1
Xie, Q1
Pan, HY1
Wu, SM1
Chen, CW1
Xu, XW1
Wang, YE1
Yao, GB1
Li, XY1
You, X1
Jie, YS1
Lin, GL1
Wu, YK1
Huang, MX1
Li, ZY1
Xie, DY1
Gao, ZL1
Chong, YT1
Keskin, O1
Wedemeyer, H1
Tüzün, A1
Zachou, K1
Deda, X1
Dalekos, GN1
Heidrich, B1
Pehlivan, S1
Zeuzem, S1
Yalçın, K1
Gürel, S1
Tabak, F1
Idilman, R1
Bozkaya, H1
Manns, M1
Yurdaydin, C1
Lampertico, P3
Invernizzi, F1
Viganò, M2
Loglio, A1
Mangia, G1
Facchetti, F1
Primignani, M1
Jovani, M1
Iavarone, M1
Fraquelli, M1
Casazza, G1
de Franchis, R1
Takaki, A1
Yasunaka, T1
Yagi, T1
Niederau, C2
Amani, A1
Thiel, A1
Lian, J1
Han, T1
Xiang, H1
Liu, F1
Lyu, H1
Wang, GL1
Qiu, P1
Zhou, SF1
Xu, LF1
Wen, P1
Wen, JB1
Xiao, XZ1
Duan, SH1
Bao, ZY1
Yuan, XD1
Liu, MS1
Giakoustidis, D1
Giouleme, O1
Vasiliadis, T1
Shi, H2
Ren, F1
Duan, Z1
Murata, K1
Asano, M1
Matsumoto, A1
Sugiyama, M1
Nishida, N1
Tanaka, E1
Inoue, T1
Sakamoto, M1
Enomoto, N1
Shirasaki, T1
Honda, M1
Kaneko, S1
Gatanaga, H1
Oka, S1
Kawamura, YI1
Dohi, T1
Shuno, Y1
Yano, H1
Mizokami, M1
Ying, H1
Wei, L1
Hong, LJ1
Chung, GE1
Cho, EJ1
Yoo, JJ1
Lee, M1
Cho, Y1
Lee, DH1
Kim, HY1
Yu, SJ1
Kim, YJ1
Yoon, JH1
Zoulim, F2
Li, DF1
Jin, ZJ1
Chen, YS1
Qiao, LM1
Yang, DH1
Xie, SF1
Wang, YM1
Zhao, NF2
Li, MW1
Lindh, M1
Uhnoo, I1
Bläckberg, J1
Duberg, AS1
Friman, S1
Fischler, B1
Karlström, O1
Norkrans, G1
Reichard, O1
Sangfeldt, P1
Söderström, A1
Sönnerborg, A1
Weiland, O2
Wejstål, R1
Wiström, J1
Parvaz, P1
Zarski, JP2
Beaugrand, M1
Benhamou, Y2
Bailly, F1
Maynard, M1
Trepo, C1
Trylesinski, A1
Monchecourt, F1
Choi, JW1
Kim, TN1
Eun, JR1
Katsounas, A1
Jochum, C1
Canbay, A1
Schlaak, J1
Gerlich, WH1
Gerken, G1
Calleja, JL1
Peñas, B1
Poynard, T1
Ngo, Y1
Hadziyannis, S1
Ratziu, V1
Chien, RN2
Liaw, YF2
Tuma, P2
Stornaiuolo, G1
Brancaccio, G1
Precone, V1
Sgrò, G1
Nardiello, S1
Gaeta, GB2
Elefsiniotis, I1
Jardi, R1
Vezali, E1
Esteban, R1
Fernández, JV1
Medrano, J1
Gong, ZJ2
Hu, DF2
Gervain, J1
Horváth, G1
Hunyady, B1
Makara, M1
Pár, A1
Szalay, F1
Tornai, I1
Telegdy, L1
Ahn, SY1
Jang, YM1
Choi, YH1
Boyd, A1
Lasnier, E1
Molina, JM1
Lascoux-Combe, C1
Bonnard, P1
Miailhes, P1
Wendum, D1
Meynard, JL1
Girard, PM1
Lacombe, K1
Marzano, A3
Marengo, A1
Andreone, P1
Volpes, R1
Canova, D1
Cursaro, C1
Riili, A1
Fiorentino, B1
Bacci, M1
Guazzini, S1
Burra, P1
Carosi, G1
Rizzetto, M4
Alberti, A1
Cariti, G1
Filice, G1
Levrero, M1
Mazzotta, F1
Pastore, G1
Piccinino, F1
Prati, D1
Raimondo, G1
Sagnelli, E1
Toti, M1
Brunetto, M1
Bruno, R1
Di Marco, V1
Ferrari, C1
Pollicino, T1
Puoti, M1
Santantonio, T1
Smedile, A1
Pradeep Kumar, S1
Medhi, S1
Asim, M1
Das, BC1
Gondal, R1
Kar, P1
Andersen, ES1
Leutscher, P1
Krarup, H1
Westin, J1
Moessner, B1
Konopski, Z1
Frigstad, SO1
Kjær, M1
Christensen, PB1
Weis, N1
Wong, GL1
Wong, VW1
Choi, PC1
Chan, AW1
Chim, AM1
Yiu, KK1
Chu, SH1
Chan, FK1
Sung, JJ1
Chan, HL1
Mo, GS1
Wu, ZL1
Zhang, JL1
Hhang, ZG1
Cai, JG1
Jie, ZH1
Wu, XG1
Shi, JP1
Montagnani, M1
Giandinoto, M1
Lisotti, A1
Galli, S1
Azzaroli, F1
Buonfiglioli, F1
Turco, L1
Aldini, R1
Mazzella, G1
Lim, SG3
Aung, MO1
Mak, B1
Sutedja, D1
Lee, YM1
Lee, GH1
Fernandes, M1
Low, HC1
Lai, V1
Dan, YY1
Sherman, M1
Ebinuma, H1
Saito, H1
Singal, AK1
Fontana, RJ2
Tujios, SR1
Lee, WM1
Naggie, S1
Sulkowski, MS1
Chang, Y1
Psevdos, G1
Sharp, V1
Köklü, S1
Tuna, Y1
Gülşen, MT1
Demir, M1
Köksal, AŞ1
Koçkar, MC1
Aygün, C1
Coban, S1
Ozdil, K1
Ataseven, H2
Akin, E1
Pürnak, T1
Yüksel, I1
Ibiş, M1
Yildirim, B1
Nadir, I1
Küçükazman, M1
Akbal, E1
Yüksel, O1
Başar, O1
Alkan, E1
Baykal, O1
Hulstaert, F1
Schwierz, C1
Nevens, F1
Thiry, N1
Gamil, M1
Colle, I1
Van de Sande, S1
Horsmans, Y1
Ristig, MB1
Crippin, J2
Aberg, JA1
Powderly, WG1
Lisker-Melman, M2
Kessels, L1
Tebas, P2
Tillmann, HL2
Bock, CT1
Bleck, JS1
Rosenau, J1
Böker, KH1
Barg-Hock, H1
Becker, T1
Trautwein, C3
Klempnauer, J2
Flemming, P2
Manns, MP2
Hadziyannis, SJ3
Papatheodoridis, GV1
Vassilopoulos, D1
LOVGREN, O1
LECOQ, R1
HURT, GA1
CHANUTIN, A1
Maier, KP1
Ristig, M1
Drechsler, H1
Chevillard, C1
Moukoko, CE1
Elwali, NE1
Bream, JH1
Kouriba, B1
Argiro, L1
Rahoud, S1
Mergani, A1
Henri, S1
Gaudart, J1
Mohamed-Ali, Q1
Young, HA1
Dessein, AJ1
Perrillo, RP1
Wiegand, J1
Tischendorf, JJ1
Nashan, B1
Niemann, P1
Rohde, P1
Lo, CM1
Cheung, ST1
Ng, IO1
Liu, CL1
Lai, CL1
Fan, ST1
Sumida, Y1
Kanemasa, K1
Tachibana, S1
Maekawa, K1
Mori, K2
Minami, M1
Okanoue, T1
Lai, CJ1
Terrault, NA1
Neff, GW1
Nery, J1
Lau, DT1
O'Brien, CB1
Duncan, R1
Shire, NJ1
Ruiz, P1
Nery, C1
Montalbano, M1
Muslu, H1
Safdar, K1
Schiff, ER1
Tzakis, AG1
Madariaga, JR1
Mazzaferro, V1
Carenzi, S1
Romito, R1
Pulvirenti, A1
Franchello, A1
Salizzoni, M1
Taltavull, TC1
Chahri, N1
Verdura, B1
Gornals, J1
Lopez, C1
Casanova, A1
Cañas, C1
Figueras, J1
Casais, LA1
Moon, W1
Choi, MS1
Moon, YM1
Koh, KC1
Yoo, BC1
Rhee, JC1
Shim, SG1
Tseng, PL1
Lu, SN1
Tung, HD1
Wang, JH1
Changchien, CS1
Lee, CM2
Tassopoulos, NC2
Heathcote, EJ2
Chang, TT2
Kitis, G2
Goodman, Z2
Ma, J2
Arterburn, S2
Xiong, S1
Currie, G1
Brosgart, CL2
Su, GG1
Ying, MF1
Kim, KM1
Choi, WB1
Lee, HC1
Chung, YH1
Lee, YS1
Spiering, W1
Kroon, AA1
de Leeuw, PW1
Yeh, CT1
Grattagliano, I1
Palmieri, VO1
Portincasa, P1
Palasciano, G1
Blaas, S1
Schneidewind, A1
Glück, T1
Salzberger, B1
Borroto-Esoda, K1
Chuck, SL1
Takamura, M1
Ichida, T1
Ohkoshi, S1
Tsubata, S1
Osaki, A1
Aoyagi, T1
Nomoto, M1
Uehara, K1
Terada, H1
Aoyagi, Y1
Ranneberg, B1
Mertenskoetter, T1
Pearce, G1
Widjaja, D1
Yarlagadda, S1
Singu, BS1
Loganathan, RS1
Blum, S1
Bloom, A1
Remy, P1
Mallet, VO1
Dhalluin-Venier, V1
Verkarre, V1
Correas, JM1
Chaix, ML1
Viard, JP1
Pol, S1
Matthews, GV1
Cooper, DA1
Dore, GJ1
Arora, G1
Keeffe, EB2
Yeon, JE1
Byun, KS1
Kim, GH1
Faria, LC1
Gigou, M1
Roque-Afonso, AM1
Sebagh, M1
Fallot, G1
Ferrari, TC1
Guettier, C1
Dussaix, E1
Castaing, D1
Brechot, C1
Ayoub, WS1
Bjersing, L1
Andersson, C1
Lithner, F1
Zaima, M1
Noguchi, M1
Wada, Y1
Ozawa, K1
Ho, Y1
Lin, HJ1
Mirvish, SS1
Medalie, J1
Linsell, CA1
Yousuf, E1
Reyad, S1
Bielik, E1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Real World Study on the Effect of HBV-DNA High-precision Detection Based Anti-viral Regimen Adjustment on Achieving Complete Virologic Response in Patients With Chronic Hepatitis B.(REACH)[NCT04724785]10,000 participants (Anticipated)Observational2020-12-01Recruiting
A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of Presumed Pre-Core Mutant Chronic Hepatitis B[NCT00117676]Phase 3382 participants (Actual)Interventional2005-02-28Completed
A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B[NCT00116805]Phase 3266 participants (Actual)Interventional2005-06-30Completed
Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial[NCT00663182]Phase 4200 participants (Anticipated)Interventional2008-01-31Enrolling by invitation
HBV Viral Suppression by Entecavir in Adefovir Partial Responders[NCT00704106]60 participants (Actual)Observational2008-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Participants With ALT Normalization at Week 48

ALT normalization was defined as ALT > upper limit of normal (ULN) at baseline and within the normal range at the end of blinded treatment. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Week 48

Interventionpercentage of participants (Number)
TDF-TDF76.3
ADV-TDF77.1

Percentage of Participants With ALT Normalization at Weeks 96

ALT normalization was defined as ALT > ULN at baseline and within the normal range at Week 96. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Week 96

Interventionpercentage of participants (Number)
TDF-TDF72.4
ADV-TDF68.5

Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48

(NCT00117676)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TDF-TDF93.2
ADV-TDF63.2

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 96

(NCT00117676)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TDF-TDF90.6
ADV-TDF89.3

Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00117676)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionunits per liter (Mean)
Week 48Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-124.4-138.5-140.0-140.3-139.5-134.7-143.1-132.6-131.9-129.2
TDF-TDF-95.0-93.7-99.1-99.6-97.7-98.9-98.9-96.1-97.0-94.9

Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00117676)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionlog10 copies/mL (Mean)
Week 48Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-4.07-4.74-4.77-4.75-4.77-4.81-4.81-4.79-4.69-4.75
TDF-TDF-4.57-4.54-4.61-4.56-4.59-4.61-4.61-4.56-4.60-4.57

Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240

The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00117676)
Timeframe: Baseline; Week 240

,
Interventionunits on a scale (Mean)
Knodell ScoreIshak Score
ADV-TDF-4.9-4.2
TDF-TDF-4.6-4.0

Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48

The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00117676)
Timeframe: Baseline; Week 48

,
Interventionunits on a scale (Mean)
Knodell Necroinflammatory ScoreIshak Necroinflammatory Score
ADV-TDF-3.4-2.6
TDF-TDF-3.5-2.6

Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00117676)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionunits per liter (Mean)
Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-0.6-0.3-3.6-3.9-4.1-2.0-3.9-8.9-5.9
TDF-TDF2.4-0.60.7-2.5-3.9-2.6-2.9-4.6-2.8

Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00117676)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionlog10 copies/mL (Mean)
Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-0.60-0.63-0.61-0.61-0.64-0.65-0.66-0.67-0.72
TDF-TDF0.02-0.030.01-0.04-0.04-0.05-0.02-0.04-0.05

Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 144 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 96 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 96 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 97 to 144

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF00000
TDF-TDF40121
TDF-TDF With Addition of FTC00000

Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 192 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 144 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 144 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 145 to 192

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF00000
TDF-TDF30111
TDF-TDF With Addition of FTC10010

Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 240 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 192 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 192 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 193 to 240

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF20002
TDF-TDF11000
TDF-TDF With Addition of FTC20200

Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 288 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 240 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 240 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 241 to 288

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF10100
TDF-TDF30210
TDF-TDF With Addition of FTC10100

Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 336 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 288 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 288 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 289 to 336

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF10001
TDF-TDF00000
TDF-TDF With Addition of FTC10010

Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 384 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 336 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 336 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 337 to 384

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF00000
TDF-TDF10001
TDF-TDF With Addition of FTC00000

Number of Participants With HBV Genotypic Changes From Baseline at Week 432 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 432 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 384 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 384 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 385 to 432

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF10100
TDF-TDF20020
TDF-TDF With Addition of FTC00000

Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 48, those with viral breakthrough, and those who discontinued after Week 24 with HBV DNA ≥ 400 copies/mL. (NCT00117676)
Timeframe: Baseline; Week 48

,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF42714201
TDF-TDF80341

Number of Participants With HBV Genotypic Changes From Baseline at Week 480 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 480 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 432 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 432 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 433 to 480

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF00000
TDF-TDF00000
TDF-TDF With Addition of FTC00000

Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 96 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 48 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 49 to 96

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF00000
TDF-TDF60240
TDF-TDF With Addition of FTC10100

Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384

ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, and 384

,
Interventionpercentage of participants (Number)
Week 144Week 192Week 240Week 288Week 336Week 384
ADV-TDF70.076.475.772.965.469.2
TDF-TDF74.368.270.369.965.965.3

Percentage of Participants With ALT Normalization at Weeks 432 and 480

ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Weeks 432 and 480

,
Interventionpercentage of participants (Number)
Week 432Week 480
ADV-TDF87.288.9
TDF-TDF86.580.0

Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Week 96

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 96. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 96. (NCT00117676)
Timeframe: Baseline; Week 96

,
Interventionpercentage of participants (Number)
HBsAg LossAnti-HBs Seroconversion
ADV-TDF00
TDF-TDF00

Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, 384, 432, and 480

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. (NCT00117676)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionpercentage of participants (Number)
HBsAg Loss - Week 144Anti-HBs Seroconversion - Week 144HBsAg Loss - Week 192Anti-HBs Seroconversion - Week 192HBsAg Loss - Week 240Anti-HBs Seroconversion - Week 240HBsAg Loss - Week 288Anti-HBs Seroconversion - Week 288HBsAg Loss - Week 336Anti-HBs Seroconversion - Week 336HBsAg Loss - Week 384Anti-HBs Seroconversion - Week 384HBsAg Loss - Week 432Anti-HBs Seroconversion - Week 432HBsAg Loss - Week 480Anti-HBs Seroconversion - Week 480
ADV-TDF00000.800.80.80.80.80.80.81.60.82.40.8
TDF-TDF00000000000.80.41.20.41.20.8

Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48

"Complete response was a composite endpoint defined as histological response and HBV DNA < 400 copies/mL. Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.~A participant was a nonresponder for the primary endpoint if either biopsy (baseline or end-of-treatment) was missing or if there was not an HBV DNA value available at or beyond Week 40." (NCT00117676)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
YesNo
ADV-TDF48.851.2
TDF-TDF70.829.2

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384

(NCT00117676)
Timeframe: Weeks 144, 192, 240, 288, 336, and 384

,
Interventionpercentage of participants (Number)
Week 144Week 192Week 240Week 288Week 336Week 384
ADV-TDF88.486.883.982.978.076.3
TDF-TDF86.784.082.880.577.074.3

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 432 and 480

(NCT00117676)
Timeframe: Weeks 432 and 480

,
Interventionpercentage of participants (Number)
Week 432Week 480
ADV-TDF97.7100.0
TDF-TDF97.6100.0

Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion Antibody to HBs (Anti-HBs) at Week 48

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 48. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 48. (NCT00117676)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
HBsAg LossSeroconversion to anti-HBs
ADV-TDF00
TDF-TDF00

Percentage of Participants With Histological Response at Week 240

Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00117676)
Timeframe: Baseline; Week 240

,
Interventionpercentage of participants (Number)
YesNo
ADV-TDF85.114.9
TDF-TDF87.312.7

Percentage of Participants With Histological Response at Week 48

Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00117676)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
YesNo
ADV-TDF68.831.2
TDF-TDF72.427.6

Ranked Assessment of Necroinflammation and Fibrosis at Week 240

Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00117676)
Timeframe: Baseline; Week 240

,
Interventionpercentage of participants (Number)
Improvement - NecroinflammationNo Change - NecroinflammationWorsening - NecroinflammationImprovement - FibrosisNo Change - FibrosisWorsening - Fibrosis
ADV-TDF94.61.44.159.533.86.8
TDF-TDF96.72.70.762.034.04.0

Ranked Assessment of Necroinflammation and Fibrosis at Week 48

Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00117676)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
Improvement - NecroinflammationNo Change - NecroinflammationWorsening - NecroinflammationMissing Data - NecroinflammationImprovement - FibrosisNo Change - FibrosisWorsening - FibrosisMissing Data - Fibrosis
ADV-TDF81.68.00.89.625.654.410.49.6
TDF-TDF82.06.84.86.422.063.28.46.4

Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48

ALT normalization was defined as ALT > upper limit of normal (ULN) at baseline and within the normal range at the end of blinded treatment. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Week 48

Interventionpercentage of participants (Number)
TDF-TDF68.0
ADV-TDF54.4

Percentage of Participants With ALT Normalization at Week 96

ALT normalization was defined as ALT > ULN at baseline and within the normal range at Week 96. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Week 96

Interventionpercentage of participants (Number)
TDF-TDF65.2
ADV-TDF74.4

Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48

"Complete response was a composite endpoint defined as histological response and HBV DNA < 400 copies/mL. Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.~A participant was a nonresponder for the primary endpoint if either biopsy (baseline or end-of-treatment) was missing or if there was not an HBV DNA value available at or beyond Week 40." (NCT00116805)
Timeframe: Baseline; Week 48

Interventionpercentage of participants (Number)
TDF-TDF66.5
ADV 10 mg12.2

Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48

(NCT00116805)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TDF-TDF76.1
ADV-TDF13.3

Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96

(NCT00116805)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TDF-TDF77.6
ADV-TDF77.9

Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00116805)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
InterventionU/L (Mean)
Week 48Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-106.1-120.4-126.2-139.6-134.8-130.9-132.3-133.7-162.1-157.5
TDF-TDF-107.2-107.8-100.7-101.4-95.9-102.3-101.9-108.1-105.0-92.3

Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00116805)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionlog10 IU/mL (Mean)
Week 48Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-3.93-6.38-6.31-6.49-6.45-6.49-6.46-6.28-6.45-6.37
TDF-TDF-6.17-6.26-6.32-6.30-6.22-6.27-6.35-6.38-6.13-6.18

Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240

The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00116805)
Timeframe: Baseline; Week 240

,
Interventionunits on a scale (Mean)
Knodell Necroinflammatory ScoreIshak Necroinflammatory Score
ADV-TDF-5.1-4.5
TDF-TDF-4.8-4.1

Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48

The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00116805)
Timeframe: Baseline; Week 48

,
Interventionunits on a scale (Mean)
Knodell Necroinflammatory ScoreIshak Necroinflammatory Score
ADV-TDF-3.2-2.6
TDF-TDF-3.6-2.7

Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00116805)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
InterventionU/L (Mean)
Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-6.9-0.7-7.8-8.1-10.3-9.3-6.9-11.6-7.1
TDF-TDF-2.0-0.4-1.33.7-1.6-1.2-4.4-4.3-5.5

Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00116805)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionlog10 IU/mL (Mean)
Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-2.43-2.27-2.41-2.49-2.62-2.59-2.34-2.32-2.16
TDF-TDF-0.10-0.19-0.20-0.14-0.18-0.25-0.29-0.13-0.24

Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 144 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 96 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 96 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 97 to 144

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF52300
ADV-TDF With Addition of FTC50031
TDF-TDF21010
TDF-TDF With Addition of FTC72320

Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 192 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 144 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 144 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 145 to 192

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF10100
ADV-TDF With Addition of FTC10100
TDF-TDF20101
TDF-TDF With Addition of FTC50013

Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 240 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 192 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 192 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 193 to 240

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF00000
ADV-TDF With Addition of FTC11000
TDF-TDF30210
TDF-TDF With Addition of FTC30021

Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 288 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 240 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 240 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 241 to 288

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF00000
ADV-TDF With Addition of FTC00000
TDF-TDF30021
TDF-TDF With Addition of FTC00000

Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 336 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 288 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 288 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 289 to 336

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF10010
ADV-TDF With Addition of FTC00000
TDF-TDF10001
TDF-TDF With Addition of FTC00000

Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 384 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 336 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 336 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 337 to 384

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF21100
ADV-TDF With Addition of FTC20110
TDF-TDF10001
TDF-TDF With Addition of FTC00000

Number of Participants With HBV Genotypic Changes From Baseline at Week 432 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 432 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 384 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 384 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 385 to 432

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF00000
ADV-TDF With Addition of FTC10010
TDF-TDF10100
TDF-TDF With Addition of FTC30030

Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL, those with viral breakthrough, and those who discontinued after Week 24 with HBV DNA ≥ 400 copies/mL. (NCT00116805)
Timeframe: Baseline; Week 48

,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF75817437
TDF-TDF3121379

Number of Participants With HBV Genotypic Changes From Baseline at Week 480 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 480 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 432 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 432 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 433 to 480

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF10010
ADV-TDF With Addition of FTC00000
TDF-TDF00000
TDF-TDF With Addition of FTC30120

Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 96 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 48 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 49 to 96

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF1621121
ADV-TDF With Addition of FTC103232
TDF-TDF1823103
TDF-TDF With Addition of FTC130157

Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384

ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, and 384

,
Interventionpercentage of participants (Number)
Week 144Week 192Week 240Week 288Week 336Week 384
ADV-TDF67.869.465.970.167.967.1
TDF-TDF60.259.650.051.346.252.6

Percentage of Participants With ALT Normalization at Weeks 432 and 480

ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Weeks 432 and 480

,
Interventionpercentage of participants (Number)
Week 432Week 480
ADV-TDF78.682.8
TDF-TDF79.675.0

Percentage of Participants With HBeAg Loss or Seroconversion to Anti-HBe at Week 96

HBeAg loss was defined as HBeAg positive at baseline and HBeAg negative at Week 96. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative at baseline to positive at Week 96. (NCT00116805)
Timeframe: Baseline; Week 96

,
Interventionpercentage of participants (Number)
HBeAg LossSeroconversion to Anti-HBe
ADV-TDF25.622.0
TDF-TDF25.922.8

Percentage of Participants With HBsAg Loss or Seroconversion to Anti-HBs at Week 96

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. (NCT00116805)
Timeframe: Baseline; Week 96

,
Interventionpercentage of participants (Number)
HBsAg LossAnti-HBs Seroconversion
ADV-TDF5.84.7
TDF-TDF5.34.1

Percentage of Participants With HBsAg Loss or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, 384, 432, and 480

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. (NCT00116805)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionpercentage of participants (Number)
HBsAg Loss - Week 144Anti-HBs Seroconversion - Week 144HBsAg Loss - Week 192Anti-HBs Seroconversion - Week 192HBsAg Loss - Week 240Anti-HBs Seroconversion - Week 240HBsAg Loss - Week 288Anti-HBs Seroconversion - Week 288HBsAg Loss - Week 336Anti-HBs Seroconversion - Week 336HBsAg Loss - Week 384Anti-HBs Seroconversion - Week 384HBsAg Loss - Week 432Anti-HBs Seroconversion - Week 432HBsAg Loss - Week 480Anti-HBs Seroconversion - Week 480
ADV-TDF8.06.87.96.78.08.08.08.07.97.99.07.910.28.010.17.9
TDF-TDF7.55.29.46.49.26.39.26.410.37.511.08.110.97.610.98.0

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384

(NCT00116805)
Timeframe: Weeks 144, 192, 240, 288, 336, and 384

,
Interventionpercentage of participants (Number)
Week 144Week 192Week 240Week 288Week 336Week 384
ADV-TDF70.571.666.364.862.160.5
TDF-TDF71.767.963.461.359.456.1

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 432 and 480

(NCT00116805)
Timeframe: Weeks 432 and 480

,
Interventionpercentage of participants (Number)
Week 432Week 480
ADV-TDF100.096.6
TDF-TDF93.098.0

Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss/Seroconversion at Week 48

HBeAg loss was defined as HBeAg positive at baseline and HBeAg negative at Week 48. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative at baseline to positive at Week 48. (NCT00116805)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
HBeAg LossHBeAg Seroconversion
ADV-TDF17.517.5
TDF-TDF22.220.9

Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion at Week 48

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 48. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 48. (NCT00116805)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
HBsAg LossHBsAg Seroconversion
ADV-TDF00
TDF-TDF3.21.3

Percentage of Participants With Histological Response at Week 240

Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00116805)
Timeframe: Baseline; Week 240

,
Interventionpercentage of participants (Number)
YesNo
ADV-TDF89.610.4
TDF-TDF88.211.8

Percentage of Participants With Histological Response at Week 48

Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00116805)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
YesNo
ADV-TDF67.832.2
TDF-TDF74.425.6

Ranked Assessment of Necroinflammation and Fibrosis at Week 240

Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00116805)
Timeframe: Baseline; Week 240

,
Interventionpercentage of participants (Number)
Improvement - NecroinflammationNo Change - NecroinflammationWorsening - NecroinflammationImprovement - FibrosisNo Change - FibrosisWorsening - Fibrosis
ADV-TDF97.92.1058.339.62.1
TDF-TDF96.13.9056.639.53.9

Ranked Assessment of Necroinflammation and Fibrosis at Week 48

Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00116805)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
Improvement - NecroinflammationNo Change - NecroinflammationWorsening - NecroinflammationMissing Data - NecroinflammationImprovement - FibrosisNo Change - FibrosisWorsening - FibrosisMissing Data - Fibrosis
ADV-TDF78.93.35.612.220.061.16.712.2
TDF-TDF81.34.53.410.819.963.65.111.4

Reviews

29 reviews available for adenine and Liver Cirrhosis

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Hepatitis Delta: Prevalence, Natural History, and Treatment Options.
    Gastroenterology clinics of North America, 2020, Volume: 49, Issue:2

    Topics: Adenine; Antibodies, Viral; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Global Health;

2020
Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:2

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Creatinine; DNA, Viral; Drug Therapy, Combination;

2014
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Adenine; Administration, Oral; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Guanine; Hepat

2014
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Guanine; Hepatitis

2014
An update on hepatitis B, D, and E viruses.
    Topics in antiviral medicine, 2014, Volume: 21, Issue:5

    Topics: Adenine; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis E

2014
Management of chronic hepatitis B in children: an unresolved issue.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:5

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Child; Databases, Bibliographic

2014
Prevention of hepatitis B virus reinfection in liver transplant recipients.
    Intervirology, 2014, Volume: 57, Issue:3-4

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B virus; Humans; Immunoglobulins; Liver;

2014
Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence.
    International journal of molecular sciences, 2015, Jul-30, Volume: 16, Issue:8

    Topics: Adenine; Antiviral Agents; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Im

2015
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
    Scandinavian journal of infectious diseases, 2008, Volume: 40, Issue:6-7

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtr

2008
[Entecavir].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 7

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug T

2008
Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.
    Best practice & research. Clinical gastroenterology, 2008, Volume: 22, Issue:6

    Topics: Adenine; Adenine Nucleotides; Alanine Transaminase; Carcinoma, Hepatocellular; DNA, Viral; Drug Admi

2008
[Role of tenofovir in HIV and hepatitis C virus coinfection].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 8

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug

2008
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:4

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Human

2011
[Prevention for the development of hepatitis B virus-related hepatocellular carcinoma by anti-viral treatment].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Interferons; Lam

2011
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combin

2012
New advances in chronic hepatitis B.
    Current opinion in gastroenterology, 2012, Volume: 28, Issue:3

    Topics: Adenine; Antiviral Agents; Coinfection; Disease Progression; Drug Resistance, Viral; Female; Guanine

2012
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
    Gastroenterology, 2012, Volume: 142, Issue:6

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease

2012
Treatment of HBeAg-negative chronic hepatitis B.
    Seminars in liver disease, 2003, Volume: 23, Issue:1

    Topics: Adenine; Antiviral Agents; Endpoint Determination; Hepatitis B e Antigens; Hepatitis B, Chronic; Hum

2003
Management of patients with decompensated HBV cirrhosis.
    Seminars in liver disease, 2003, Volume: 23, Issue:1

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance; Hepatiti

2003
[Hepatitis: associated diseases. Risk groups -- prevention -- treatment].
    Praxis, 2003, Aug-13, Volume: 92, Issue:33

    Topics: Adenine; Adult; Antiviral Agents; Child; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B S

2003
Management of the patient with hepatitis B virus-related cirrhosis.
    Journal of hepatology, 2003, Volume: 39 Suppl 1

    Topics: Adenine; Antiviral Agents; Hepatitis B; Humans; Interferons; Lamivudine; Liver Cirrhosis; Nucleoside

2003
Management of hepatitis B in liver transplantation patients.
    Seminars in liver disease, 2004, Volume: 24 Suppl 1

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lam

2004
Antiviral therapy in patients with chronic hepatitis B and cirrhosis.
    Gastroenterology clinics of North America, 2004, Volume: 33, Issue:3

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhos

2004
[Liver transplantation for complications of hepatitis B].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:2 Pt 2

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combinati

2006
[Therapy of hepatitis B virus infection].
    Praxis, 2006, Sep-06, Volume: 95, Issue:36

    Topics: Adenine; Antiviral Agents; Drug Antagonism; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Co

2006
[Managing resistance to analogue antiviral drugs in a decompensated cirrhosis patient].
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:10 Pt 2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hep

2006
Chronic hepatitis B with advanced fibrosis or cirrhosis: impact of antiviral therapy.
    Reviews in gastroenterological disorders, 2007,Spring, Volume: 7, Issue:2

    Topics: Adenine; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatit

2007
Review article: current antiviral therapy of chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2008, Volume: 28, Issue:2

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Resistance, Viral; Emtrici

2008

Trials

29 trials available for adenine and Liver Cirrhosis

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
    BMC gastroenterology, 2017, Aug-30, Volume: 17, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens

2017
Effects of the combined administration of entecavir and adefovir dipivoxil to improve hepatic fibrosis in hepatitis B patients with interferon resistance.
    Minerva medica, 2017, Volume: 108, Issue:6

    Topics: Adenine; Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Creat

2017
Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis.
    World journal of gastroenterology, 2013, Jun-14, Volume: 19, Issue:22

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Chi-Square Distribution; China;

2013
De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis.
    World journal of gastroenterology, 2013, Oct-07, Volume: 19, Issue:37

    Topics: Adenine; Adult; Alanine Transaminase; Analysis of Variance; Antiviral Agents; Biomarkers; Chi-Square

2013
Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:10

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination;

2014
Curative effect of combined lamivudine, adefovir dipivoxil, and stem cell transplantation on decompensated hepatitis B cirrhosis.
    Genetics and molecular research : GMR, 2014, Feb-21, Volume: 13, Issue:4

    Topics: Adenine; alpha-Fetoproteins; Cholinesterases; Combined Modality Therapy; Female; Hepatitis B virus;

2014
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:1

    Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I

2015
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:1

    Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I

2015
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:1

    Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I

2015
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:1

    Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I

2015
Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015, Volume: 13, Issue:13

    Topics: Adenine; Adult; Antiviral Agents; Biopsy; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatiti

2015
[A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2015, Volume: 23, Issue:10

    Topics: Adenine; Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferas

2015
Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B virus; Hepatit

2016
[Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2016, Volume: 36, Issue:5

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; DNA, Viral;

2016
Effect of nucleoside analogues in the treatment of hepatitis B cirrhosis and its effect on Th17 cell.
    European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; L

2017
[Adefovir dipivoxil treatment of hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2008, Volume: 16, Issue:5

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Female; Glomerulonephritis; Hepatitis B; Hepatitis B v

2008
[Lamivudine and adefovir dipivoxil combination treatment for liver cirrhosis patients with CHB].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2008, Volume: 16, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B;

2008
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Biopsy; Double-Blind Method; Female; Hepatitis B e Ant

2009
[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:7

    Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Collagen; DNA, Viral; Drug Resistance,

2009
Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis.
    The Indian journal of medical research, 2011, Volume: 133

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Drug Resistance, Viral; Female; Hepatitis B

2011
[One-year combination therapy de novo of adefovir dipivoxil and lamivudine for decompensated cirrhosis related to HBV].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2011, Volume: 25, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; China; Drug Therapy, Combination; Female; Hepatitis B virus; Human

2011
Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis.
    Journal of clinical gastroenterology, 2011, Volume: 45, Issue:9

    Topics: Adenine; Aged; Antiviral Agents; Cohort Studies; Disease Progression; Drug Therapy, Combination; Fem

2011
[Experimental study on effect of dahuang zhechong wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2012, Volume: 37, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination;

2012
[Efficacy of combination therapy of lamivudine and adefovir dipivoxyl for patients with hepatitis B-induced decompensated liver cirrhosis].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2012, Volume: 37, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepati

2012
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
    The Journal of infectious diseases, 2002, Dec-15, Volume: 186, Issue:12

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; H

2002
Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatic Encephalopathy; Hepa

2005
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    The New England journal of medicine, 2005, Jun-30, Volume: 352, Issue:26

    Topics: Adenine; Adolescent; Adult; Animals; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Adminis

2005
Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus.
    Journal of Korean medical science, 2005, Volume: 20, Issue:5

    Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiviral Agents; Drug Combinations; Drug Resistance, V

2005
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
    Gastroenterology, 2006, Volume: 131, Issue:6

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral;

2006
[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2007, Volume: 15, Issue:11

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis, Chronic; Humans;

2007
Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
    Gastroenterology, 2008, Volume: 134, Issue:7

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Circular; DNA, V

2008

Other Studies

79 other studies available for adenine and Liver Cirrhosis

ArticleYear
Differentiation-inducing factor-1 prevents hepatic stellate cell activation through inhibiting GSK3β inactivation.
    Biochemical and biophysical research communications, 2019, 11-26, Volume: 520, Issue:1

    Topics: Active Transport, Cell Nucleus; Adenine; Animals; Antineoplastic Agents; beta Catenin; Cell Differen

2019
Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis.
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:9

    Topics: Acidosis, Lactic; Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therap

2017
Can We Trust Safety of Tenofovir Disoproxil in Patients with Decompensated Cirrhosis?
    Gut and liver, 2017, 11-15, Volume: 11, Issue:6

    Topics: Adenine; Humans; Liver Cirrhosis; Organophosphonates; Tenofovir

2017
Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
    Medicine, 2017, Volume: 96, Issue:44

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepatitis B

2017
Trolline Ameliorates Liver Fibrosis by Inhibiting the NF-κB Pathway, Promoting HSC Apoptosis and Suppressing Autophagy.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 44, Issue:2

    Topics: Adenine; Alkaloids; Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; bcl-2-Associated X P

2017
Chronic hepatitis B virus and liver fibrosis: A mathematical model.
    PloS one, 2018, Volume: 13, Issue:4

    Topics: Adenine; Computer Simulation; Diffusion; Drug Delivery Systems; Hepatic Stellate Cells; Hepatitis B

2018
β-Arrestin1 enhances liver fibrosis through autophagy-mediated Snail signaling.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:2

    Topics: Adenine; Animals; Autophagy; beta-Arrestin 1; Cell Line; Female; Glycogen Synthase Kinase 3 beta; He

2019
Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels.
    Journal of cellular biochemistry, 2019, Volume: 120, Issue:4

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Disease Management; DNA, Viral; Fema

2019
Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2019, Volume: 29, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; China; Female; Guanine; Hepatitis

2019
Fibrosing Cholestatic Hepatitis-Like Syndrome in an Immunocompetent Patient With an Acute Flare of Chronic Hepatitis B.
    Hepatology (Baltimore, Md.), 2019, Volume: 70, Issue:4

    Topics: Adenine; Biopsy, Needle; Cholestasis; Disease Progression; Follow-Up Studies; Hepatitis B, Chronic;

2019
Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
    European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:11

    Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B Surf

2019
Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Antiviral therapy, 2013, Volume: 18, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Administrat

2013
[Treatment of one advanced schistosomiasis patient with hepatitis B cirrhosis by lamivudine and adefovir dipivoxil].
    Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control, 2013, Volume: 25, Issue:1

    Topics: Adenine; Adult; Hepatitis B virus; Humans; Lamivudine; Liver Cirrhosis; Male; Organophosphonates; Sc

2013
Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective.
    Antiviral research, 2013, Volume: 100, Issue:2

    Topics: Adenine; Adult; Aged; Bilirubin; Creatinine; DNA, Viral; Female; Hepatitis B, Chronic; Humans; India

2013
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.
    Clinical and molecular hepatology, 2013, Volume: 19, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Administration Schedul

2013
Expression and function of methylthioadenosine phosphorylase in chronic liver disease.
    PloS one, 2013, Volume: 8, Issue:12

    Topics: Adenine; Animals; Apoptosis; Chronic Disease; Gene Expression Regulation; Hepatic Stellate Cells; He

2013
New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence.
    Transplant international : official journal of the European Society for Organ Transplantation, 2014, Volume: 27, Issue:10

    Topics: Adenine; Adult; Cohort Studies; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Guanine;

2014
Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus.
    Clinical and molecular hepatology, 2014, Volume: 20, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female;

2014
Antiviral therapy of chronic hepatitis B.
    Intervirology, 2014, Volume: 57, Issue:3-4

    Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Gene Products, pol; Gu

2014
Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients.
    AIDS (London, England), 2014, Oct-23, Volume: 28, Issue:16

    Topics: Adenine; Adult; Antiviral Agents; Hepatitis D, Chronic; HIV Infections; Humans; Liver Cirrhosis; Mal

2014
Liver biopsy interpretation & the regression of hepatitis B virus related cirrhosis.
    The Indian journal of medical research, 2014, Volume: 140, Issue:2

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biomarkers; Biopsy; Hepatitis B, Chronic; Humans; I

2014
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:11-12

    Topics: Adenine; Adult; Antiviral Agents; Canada; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e

2014
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.
    Clinical and molecular hepatology, 2014, Volume: 20, Issue:3

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA

2014
Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study.
    World journal of gastroenterology, 2015, Jan-14, Volume: 21, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; China; DNA, Viral; Drug Resistance, Viral; Drug Therap

2015
Entecavir Combined With Adefovir Ameliorates Patients With Chronic Hepatitis B Who Fail to Respond to Nucleotide (Acid) Analog Monotherapy.
    American journal of therapeutics, 2017, Volume: 24, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies;

2017
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
    Journal of hepatology, 2015, Volume: 63, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Elasticity Ima

2015
Long-term follow-up of HBsAg-positive patients in Germany.
    European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:1

    Topics: Adenine; Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy,

2016
Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Transplant infectious disease : an official journal of the Transplantation Society, 2016, Volume: 18, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Guanin

2016
Naringin in Ganshuang Granule suppresses activation of hepatic stellate cells for anti-fibrosis effect by inhibition of mammalian target of rapamycin.
    Journal of cellular and molecular medicine, 2017, Volume: 21, Issue:3

    Topics: Adenine; Animals; Autophagy; Cells, Cultured; Drugs, Chinese Herbal; Fibrosis; Flavanones; Hepatic S

2017
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asymptomatic Infections; Carcinoma, Hepat

2018
Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
    Clinical and molecular hepatology, 2017, Volume: 23, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral;

2017
Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:3

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Cohort Studies; Drug Resistance; Female; Genotype; Hepat

2009
[A case of severe hypophosphatemia related to adefovir dipivoxil treatment in a patient with liver cirrhosis related to hepatitis B virus].
    The Korean journal of hepatology, 2008, Volume: 14, Issue:3

    Topics: Absorptiometry, Photon; Adenine; Adult; Antiviral Agents; Bone Density; DNA, Viral; Drug Resistance,

2008
Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
    European journal of medical research, 2008, Oct-27, Volume: 13, Issue:10

    Topics: Adenine; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Hepatitis B virus;

2008
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare.
    Le infezioni in medicina, 2009, Volume: 17, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hep

2009
Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.
    European journal of internal medicine, 2009, Volume: 20, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance,

2009
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
    Journal of HIV therapy, 2009, Volume: 14, Issue:1

    Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guan

2009
[Protocol for the antiviral therapy of hepatitis B and D].
    Orvosi hetilap, 2010, Jan-03, Volume: 151, Issue:1

    Topics: Adenine; Antiviral Agents; Biopsy; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface

2010
[A case of osteomalacia related to adefovir in a patient with chronic hepatitis B].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2010, Volume: 56, Issue:2

    Topics: Adenine; Aged; Alkaline Phosphatase; Antiviral Agents; Dietary Supplements; DNA, Viral; Hepatitis B,

2010
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.
    Antiviral therapy, 2010, Volume: 15, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort

2010
[Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
    Gastroenterologie clinique et biologique, 2010, Volume: 34 Suppl 2

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Guanine; Hepatitis B

2010
Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation.
    Minerva medica, 2010, Volume: 101, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis B; Hepatitis

2010
Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs.
    Scandinavian journal of gastroenterology, 2011, Volume: 46, Issue:6

    Topics: Adenine; Adult; Elasticity Imaging Techniques; Female; Hepatitis B; Humans; Lamivudine; Liver; Liver

2011
On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients.
    Antiviral therapy, 2011, Volume: 16, Issue:2

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Disease Progression; Elasticit

2011
High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on.
    Digestive diseases and sciences, 2012, Volume: 57, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Huma

2012
Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2011, Volume: 25, Issue:10

    Topics: Adenine; Antiviral Agents; Canada; Drug Approval; Guanine; Health Services Accessibility; Hepatitis

2011
Five-year review of HIV-hepatitis B virus (HBV) co-infected patients in a New York City AIDS center.
    Journal of Korean medical science, 2012, Volume: 27, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Female; Hepatitis B; Hepatitis B e Antigens; HIV Infec

2012
Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:1

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Blood Chemical Analysis; Drug Therapy,

2013
Should chronic hepatitis B be treated as early as possible?
    International journal of technology assessment in health care, 2013, Volume: 29, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Belgium; Cost-Benefit Analysis; Early Diagnosis; Guanine; Health C

2013
Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2003, Volume: 9, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Bacterial Infections; Cholestasis; Drug Resistance, Microbial; Fib

2003
The concentration of adenine in red blood cells in cirrhosis of liver.
    Acta haematologica, 1954, Volume: 12, Issue:1

    Topics: Adenine; Erythrocytes; Humans; Liver Cirrhosis

1954
[Adenine deficiency in the grave manifestations of chronic alcoholism].
    Comptes rendus hebdomadaires des seances de l'Academie des sciences, 1955, Sep-26, Volume: 241, Issue:13

    Topics: Adenine; Alcoholism; Humans; Liver Cirrhosis; Mental Disorders; Psychoses, Alcoholic; Psychotic Diso

1955
ORGANIC PHOSPHATE COMPOUNDS OF ERYTHROCYTES FROM INDIVIDUALS WITH CIRRHOSIS OF THE LIVER.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1965, Volume: 118

    Topics: Adenine; Erythrocytes; Glycerophosphates; Hexosephosphates; Humans; Liver Cirrhosis; Nucleosides; Nu

1965
Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus.
    AIDS patient care and STDs, 2003, Volume: 17, Issue:9

    Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B viru

2003
IFN-gamma polymorphisms (IFN-gamma +2109 and IFN-gamma +3810) are associated with severe hepatic fibrosis in human hepatic schistosomiasis (Schistosoma mansoni).
    Journal of immunology (Baltimore, Md. : 1950), 2003, Nov-15, Volume: 171, Issue:10

    Topics: Adenine; DNA; Genetic Predisposition to Disease; Genotype; Guanine; Humans; Interferon-gamma; Liver

2003
Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
    Zeitschrift fur Gastroenterologie, 2004, Volume: 42, Issue:1

    Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hep

2004
Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2004, Volume: 10, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Cholestasis, Intrahepatic; Drug Resistance, Viral; Drug Therapy, C

2004
[A case of liver cirrhosis B resistant to lamivudine showing the clinical effect of adefovir dipivoxil].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2004, Volume: 101, Issue:5

    Topics: Adenine; Amino Acid Motifs; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hep

2004
Tenofovir therapy for lamivudine resistance following liver transplantation.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; Chronic Disease; Drug Resistance, Viral; Hepatitis B; Hepatitis B,

2004
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2005, Volume: 11, Issue:5

    Topics: Adenine; Adult; Antibodies, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B Surface Ant

2005
Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results.
    Transplant international : official journal of the European Society for Organ Transplantation, 2005, Volume: 18, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hep

2005
[Efficacy and safety of adefovir dipivoxil in patients with decompensated liver cirrhosis with Lamivudine resistance compared to patients with compensated liver disease].
    The Korean journal of hepatology, 2005, Volume: 11, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B; Humans; Lamivud

2005
[Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2005, Volume: 34, Issue:5

    Topics: Adenine; Adult; Aged; Amino Acid Motifs; Antiviral Agents; DNA-Directed DNA Polymerase; Female; Hepa

2005
A116C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:11

    Topics: Adenine; Alleles; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cytosine; Heart

2005
Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:4

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Bilirubin; DNA, Viral; Drug Resistance

2006
Adefovir dipivoxyl for the treatment of delta-related liver cirrhosis.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:9

    Topics: Adenine; Female; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Liver Cirrhosis; Middle Aged;

2006
Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases.
    AIDS (London, England), 2006, Aug-22, Volume: 20, Issue:13

    Topics: Acute Kidney Injury; Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; H

2006
Decompensated lamivudine-resistant hepatitis B virus-related cirrhosis treated successfully with adefovir dipivoxil allowing surgery for hepatocellular carcinoma.
    Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:7

    Topics: Adenine; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Disease Progression; Drug Resis

2007
Response to Blaas et al., 'Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases'.
    AIDS (London, England), 2007, Mar-30, Volume: 21, Issue:6

    Topics: Acute Kidney Injury; Adenine; HIV Infections; Humans; Liver Cirrhosis; Organophosphonates; Reverse T

2007
Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital.
    Journal of the National Medical Association, 2007, Volume: 99, Issue:4

    Topics: Adenine; Adolescent; Adult; Black or African American; Contraindications; Female; Hepatitis B, Chron

2007
Reversibility of cirrhosis in HIV/HBV coinfection.
    Antiviral therapy, 2007, Volume: 12, Issue:2

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, V

2007
Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
    Antiviral therapy, 2007, Volume: 12, Issue:1

    Topics: Adenine; CD4 Lymphocyte Count; DNA, Viral; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; H

2007
[New German and American guidelines for therapy of hepatitis B. Discrepancies and similarities].
    Medizinische Klinik (Munich, Germany : 1983), 2007, Sep-15, Volume: 102, Issue:9

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resistance, Viral; Drug Th

2007
Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis.
    Liver international : official journal of the International Association for the Study of the Liver, 2008, Volume: 28, Issue:6

    Topics: Adenine; Adult; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigen

2008
Hepatocellular carcinoma in patients from northern Sweden with acute intermittent porphyria: morphology and mutations.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 1996, Volume: 5, Issue:5

    Topics: Adenine; Aged; Aged, 80 and over; Alleles; Base Sequence; Carcinoma, Hepatocellular; Cell Division;

1996
Sequential decrease in platelet energy charge after hepatic resection in cirrhotics.
    American journal of surgery, 1990, Volume: 159, Issue:2

    Topics: Adenine; Adenosine Triphosphate; Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blood Platelet

1990
Patterns of excretion of methylated purines in hepatocellular carcinoma.
    Cancer research, 1974, Volume: 34, Issue:5

    Topics: Adenine; Adult; Carcinoma, Hepatocellular; Chromatography, Paper; Creatine; Guanine; Humans; Hydroly

1974
7-methylguanine and other minor urinary purines: values for normal subjects from Israel, Gaza, and Kenya, and for patients with cancer of various organs or cirrhosis of the liver.
    Cancer, 1971, Volume: 27, Issue:3

    Topics: Adenine; Adult; Aged; Arabia; Child; Creatinine; Female; Humans; Hypoxanthines; Israel; Kenya; Liver

1971
[Dihydroxyacetone metabolism in blood hemolysates of subjects with liver cirrhosis].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1967, Feb-01, Volume: 22, Issue:3

    Topics: Acetone; Adenine; Adenosine Triphosphate; Erythrocytes; Hemolysis; Humans; Liver Cirrhosis; Nucleosi

1967